Background: Identifying immunologic mechanisms that contribute to premature cardiovascular disease (CVD) among HIV-positive patients will inform prevention strategies.
Methods: Coronary artery calcium (CAC) progression was studied in an HIV cohort. Immunophenotypes were measured on baseline cryopreserved peripheral blood mononuclear cells using multicolor flow cytometry. Logistic regression identified predictors of CAC progression after adjusting for traditional and HIV-related risk factors.
Results: Baseline characteristics for the analysis cohort (n = 436) were median age 42 years, median CD4+ cell count 481 cells/μl, and 78% receiving antiretroviral therapy. Higher frequencies of CD16+ monocytes were associated with greater likelihood of CAC progression, after adjusting for traditional and HIV risk factors [odds ratio per doubling was 1.66 for CD14+/CD16+ (P = 0.02), 1.36 for CD14dim/CD16+ (P = 0.06), and 1.69 for CD14var/CD16+ (P = 0.01)]. Associations for CD16+ monocytes persisted when restricted to participants with viral suppression. We found no significant associations for CAC progression with other cellular phenotypes, including T-cell activation and senescence markers.
Conclusion: Circulating CD16+ monocytes, potentially reflecting a more pro-atherogenic subpopulation, independently predicted greater CAC progression among HIV-infected persons at low risk for AIDS. In contrast to T-cell abnormalities classically associated with AIDS-related disease progression, these data highlight the potential role of monocyte activation in HIV-related CVD risk.
aDepartment of Medicine, University of Minnesota
bDivision of Infectious Diseases, Hennepin County Medical Center
cDivision of Biostatistics, University of Minnesota, Minneapolis, Minnesota
dNational Institute of Allergy and Infectious Disease (NIAID), NIH, Bethesda, Maryland
eNational Jewish Medical and Research Center, Denver, Colorado
fWashington University School of Medicine, St Louis, Missouri
gMiriam Hospital, Providence, Rhode Island
hDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia
iAtherosclerosis Research Unit, University of Southern California
jLos Angeles Biomedical Research Institute at Harbor-UCLA, Los Angeles, California, USA.
Correspondence to Jason Baker, MD, MS, 701 Park Avenue (MC G5), Minneapolis, MN 55415, USA. Tel: +1 612 873 2705; e-mail: email@example.com
Received 22 September, 2013
Revised 8 November, 2013
Accepted 8 November, 2013
Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 3–6 March 2013, Abstract #66LB.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).